If You Invested in Climb Bio (CLYM)

Climb Bio, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. According to multiple company disclosures, its pipeline centers on monoclonal antibody product candidates designed to modulate B-cell biology and related pathways that drive autoimmune and B-cell mediated disorders.

Core Focus and Therapeutic Area

Climb Bio describes itself as a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. Its work is concentrated in B-cell mediated and autoantibody-driven conditions, where abnormal immune responses contribute to serious renal and hematologic disease. The company’s programs are being advanced in indications such as primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), and IgA nephropathy (IgAN), as reflected in its press releases and SEC filings.

Pipeline Overview

The company’s pipeline includes two named monoclonal antibody programs:

• Budoprutug: an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and is being developed for a broad range of B-cell mediated, immune-driven diseases.
• CLYM116: an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being advanced for IgA nephropathy and other B-cell mediated diseases where APRIL plays a critical role.

Climb Bio reports that budoprutug has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of primary membranous nephropathy. Company communications also state that CLYM116 is being advanced under an exclusive license and technology transfer agreement outside Greater China with Beijing Mabworks Biotech Co., Ltd.

Budoprutug: Anti-CD19 Monoclonal Antibody

Budoprutug is described in Climb Bio’s news releases as a clinical-stage, anti-CD19 monoclonal antibody developed to address a broad range of B-cell mediated, immune-driven diseases. The molecule targets CD19-expressing B cells, including plasmablasts or plasma blasts that are key sources of pathogenic autoantibodies. Company materials note that budoprutug has demonstrated B-cell depletion and is being evaluated in multiple clinical trials across three lead indications:

• Primary membranous nephropathy (pMN), through the open-label, dose-ranging Phase 2 PrisMN trial, which is designed to assess safety, pharmacokinetics, pharmacodynamics (including B cells, anti-PLA2R, and total immunoglobulin), and preliminary efficacy measures such as complete and partial remission, and to identify a dose to carry forward into Phase 3 development.
• Immune thrombocytopenia (ITP), in an open-label, dose-escalation Phase 1b/2a trial in relapsed or refractory patients, designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy, including B-cell depletion and platelet counts.
• Systemic lupus erythematosus (SLE), in a global, open-label, dose-escalation Phase 1b trial in moderate to severe disease, designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy, including B-cell depletion, autoantibody levels, and clinical activity.

Climb Bio has also initiated a Phase 1 trial of a subcutaneous formulation of budoprutug in healthy volunteers to evaluate bioavailability, pharmacokinetics, and pharmacodynamics, including B-cell depletion. Company disclosures emphasize that a subcutaneous formulation is in development to enable broader patient access and potential home-based dosing.

In an 8-K filing and related press release, Climb Bio highlighted long-term follow-up clinical data from a previously conducted Phase 1b trial of budoprutug in pMN (NCT04652570). The company reports that in this small cohort, long-term control of proteinuria was observed for up to three years after initial dosing in four patients who received up to four doses of budoprutug, and that in three of these patients no further immunosuppressive treatment was required. The company also notes that no treatment-related adverse events grade 3 or higher were observed in that study.

CLYM116: Anti-APRIL ‘Sweeper’ Monoclonal Antibody

CLYM116 is described as a monoclonal antibody targeting APRIL, a key driver of pathogenic B-cell activity in autoimmune diseases. Company communications state that CLYM116 employs a pH-dependent bind-and-release “sweeper” mechanism designed to potently block APRIL signaling, promote lysosomal degradation of APRIL, and recycle the antibody to extend its half-life. Climb Bio reports that this design offers the potential for rapid, deep, and durable inhibition of APRIL with a favorable safety profile and less frequent dosing.

According to Climb Bio’s press releases and 8-K filings, CLYM116 is being advanced for the treatment of IgA nephropathy (IgAN), a progressive autoantibody-mediated renal disease characterized by APRIL-mediated production of pathogenic IgA and deposition of immune complexes in the glomeruli. The company has presented preclinical data, including nonhuman primate studies comparing CLYM116 to sibeprenlimab, a first-generation anti-APRIL monoclonal antibody. In these preclinical models, Climb Bio reports that CLYM116 demonstrated:

• High bioavailability with subcutaneous administration and a favorable tolerability profile.
• Prolonged exposure and an approximately two- to three-fold longer half-life compared with sibeprenlimab across doses.
• Deeper and more prolonged IgA reduction after a single subcutaneous dose at equivalent dosing, with greater than 70% maximal reduction in IgA observed with CLYM116 in the reported nonhuman primate study.

Additional in vivo studies in mice described by the company showed enhanced APRIL elimination and antibody recycling relative to sibeprenlimab. Climb Bio has obtained regulatory clearance to initiate a Phase 1 clinical trial of CLYM116 in healthy volunteers and has reported dosing of the first subjects in that study. In parallel, its partner Mabworks has received regulatory clearance to initiate a Phase 1 trial in China, which the company expects will provide a complementary dataset.

Clinical Development Footprint

Across its portfolio, Climb Bio reports that it has achieved numerous regulatory clearances to conduct clinical trials and has activated trial sites in multiple countries. The company’s disclosures describe ongoing clinical activity in:

• Phase 2 development for budoprutug in pMN (PrisMN trial).
• Phase 1b/2a development for budoprutug in ITP.
• Phase 1b development for budoprutug in SLE, including a planned or cleared parallel Phase 1b trial in China that may enroll patients with lupus nephritis.
• Phase 1 evaluation of a subcutaneous formulation of budoprutug in healthy volunteers.
• Phase 1 evaluation of CLYM116 in healthy volunteers, following completion of IND-enabling studies and regulatory clearance.

Company statements emphasize that these studies are designed to generate pharmacokinetic, pharmacodynamic, safety, tolerability, and preliminary efficacy data that can inform later-stage development and potential expansion into additional immune-mediated diseases.

Corporate and Capital Markets Profile

Climb Bio, Inc. is listed on The Nasdaq Global Market under the ticker symbol CLYM, as confirmed in its Form 8-K filings, which identify its common stock, par value $0.0001 per share, as registered under Section 12(b) of the Securities Exchange Act of 1934. The company is based in Wellesley Hills, Massachusetts, as indicated by its SEC filings.

Climb Bio has reported the use of equity-based inducement awards under its 2025 Inducement Plan in connection with hiring senior executives and other employees. The company has also disclosed amendments to increase the share reserve under this plan, reflecting its use of stock options as part of its compensation and talent recruitment strategy in support of its clinical and corporate objectives.

Position Within Biotechnology and Healthcare

Within the broader healthcare sector, Climb Bio fits within the biotechnology industry segment, with a focus on clinical-stage development rather than commercialized products. Its programs target mechanisms implicated in B-cell mediated and autoantibody-driven diseases, particularly in nephrology and hematology, as illustrated by its work in IgA nephropathy, primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. Company disclosures repeatedly highlight the potential for its product candidates to address high unmet medical needs in these areas.

Stock and Investor Considerations

For investors researching CLYM stock, Climb Bio’s public materials emphasize its status as a clinical-stage company with a pipeline that includes budoprutug and CLYM116. Its SEC filings and press releases provide details on trial design, regulatory milestones, and preclinical and early clinical data, as well as information on its use of equity compensation and cash runway expectations. As with many clinical-stage biotechnology companies, the value proposition described in its communications is closely tied to the progress and outcomes of its clinical trials, regulatory interactions, and its ability to advance its investigational therapies through development.

FAQs About Climb Bio, Inc.